(Q44685491)

5 December 2017

title

Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis (English)

1 reference

5 December 2017

1 reference

1 reference

N Undre

1

1 reference

5 December 2017

P Stevenson

series ordinal

2

1 reference

5 December 2017

E Baraldi

series ordinal

3

1 reference

5 December 2017

publication date

29 September 2011

1 reference

European Journal of Drug Metabolism and Pharmacokinetics

5 December 2017

published in

1 reference

5 December 2017

volume

37

1 reference

5 December 2017

issue

1

1 reference

5 December 2017

page(s)

31-38

1 reference

In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Safety and pharmacokinetics of repeat-dose micafungin in young infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Recurring Candida albicans esophagitis in a HIV-infected patient undergoing long-Term antiretroviral therapy, and with absent-negligible immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

The impact of esophageal candidiasis on hospital charges and costs across patient subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-011-0063-8

Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21956255

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21956255

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21956255

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13318-011-0063-8

1 reference

5 December 2017

1 reference